NasdaqGS:CRTX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer’s disease and other degenerative disorders. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Cortexyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CRTX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.7%

CRTX

-3.4%

US Biotechs

-2.4%

US Market


1 Year Return

124.9%

CRTX

35.9%

US Biotechs

18.2%

US Market

Return vs Industry: CRTX exceeded the US Biotechs industry which returned 39.3% over the past year.

Return vs Market: CRTX exceeded the US Market which returned 19.5% over the past year.


Shareholder returns

CRTXIndustryMarket
7 Day-1.7%-3.4%-2.4%
30 Day-11.7%0.7%4.2%
90 Day14.5%-4.7%6.3%
1 Year124.9%124.9%38.3%35.9%20.9%18.2%
3 Yearn/a18.5%12.5%41.2%31.8%
5 Yearn/a17.2%8.9%84.8%63.9%

Price Volatility Vs. Market

How volatile is Cortexyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cortexyme undervalued compared to its fair value and its price relative to the market?

7.26x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CRTX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CRTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CRTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CRTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CRTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CRTX is overvalued based on its PB Ratio (7.3x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Cortexyme forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-8.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if CRTX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CRTX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CRTX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Cortexyme performed over the past 5 years?

-174.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CRTX is currently unprofitable.

Growing Profit Margin: CRTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CRTX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: CRTX has a negative Return on Equity (-27.75%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cortexyme's financial position?


Financial Position Analysis

Short Term Liabilities: CRTX's short term assets ($151.6M) exceed its short term liabilities ($13.7M).

Long Term Liabilities: CRTX's short term assets ($151.6M) exceed its long term liabilities ($50.0K).


Debt to Equity History and Analysis

Debt Level: CRTX is debt free.

Reducing Debt: CRTX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CRTX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 58.9% each year.


Next Steps

Dividend

What is Cortexyme current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Casey Lynch (46 yo)

6.25yrs

Tenure

US$559,952

Compensation

Ms. Casey C. Lynch has been Director of California Life Sciences Association since August 20, 2019. Ms. Lynch is Co-Founder of Cortexyme, Inc. and serves as its Chief Executive Officer, President and Direc ...


CEO Compensation Analysis

Compensation vs Market: Casey's total compensation ($USD559.95K) is below average for companies of similar size in the US market ($USD4.44M).

Compensation vs Earnings: Casey's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Casey Lynch
Co-Founder6.25yrsUS$559.95k4.21%
$ 62.8m
Stephen Dominy
Co-Founder4.83yrsno data4.87%
$ 72.7m
Michael Detke
Chief Medical Officer1.83yrsUS$1.10m0.096%
$ 1.4m
Christopher Lowe
CFO & Treasurer1.75yrsUS$437.54kno data
Caryn McDowell
Chief Legal & Administrative Officer and Corporate Secretary0.42yrno datano data
Leslie Holsinger
Executive Vice President of Research & Development2.75yrsno datano data

1.8yrs

Average Tenure

51.5yo

Average Age

Experienced Management: CRTX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Casey Lynch
Co-Founder6.25yrsUS$559.95k4.21%
$ 62.8m
Stephen Dominy
Co-Founder4.83yrsno data4.87%
$ 72.7m
Una Ryan
Lead Independent Non-Management Director1.42yrsUS$473.25k0.0097%
$ 145.5k
Ilan Zipkin
Member of Scientific Advisory Boardno dataUS$44.84kno data
Jeffrey Cummings
Member of Clinical Advisory Board1.33yrsno datano data
Kevin Young
Independent Director1.75yrsUS$472.50k0.10%
$ 1.5m
Martin Farlow
Member of Clinical Advisory Boardno datano datano data
David Lamond
Independent Director4.83yrsUS$33.75k6.95%
$ 103.7m
Christopher Senner
Independent Director1.58yrsUS$742.12k0%
$ 0
Margaret McLoughlin
Independent Director4.83yrsUS$1.07m0.0019%
$ 27.9k
Mark Brody
Member of Clinical Advisory Boardno datano datano data
David Munoz
Member of Clinical Advisory Boardno datano datano data

1.8yrs

Average Tenure

59.5yo

Average Age

Experienced Board: CRTX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.9%.


Top Shareholders

Company Information

Cortexyme, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cortexyme, Inc.
  • Ticker: CRTX
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.492b
  • Shares outstanding: 29.49m
  • Website: https://www.cortexyme.com

Number of Employees


Location

  • Cortexyme, Inc.
  • 269 East Grand Avenue
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRTXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2019

Biography

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer’s disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-admini ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 01:27
End of Day Share Price2020/10/19 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.